Premium
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
Author(s) -
Chan H. L. Y.,
Chen C. J.,
Omede O.,
Al Qamish J.,
Al Naamani K.,
Bane A.,
Tan S. S.,
Simonova M.,
Cardenas I.,
Derbala M.,
Akin O.,
Phillips R. O.,
Abdelmageed M. K.,
Abdulla M.,
Adda D.,
Al Baqali A.,
Al Dweik N.,
Al Ejji K.,
Al ghazzawi I.,
Al Kaabi S.,
Al Sadadi M.,
Al Salman J.,
AlBadri M.,
AlBusafi S. A.,
AlRomaihi H. E.,
Ampofo W.,
Antonov K.,
Anyaike C.,
Arome F.,
Blach S.,
Borodo M. M.,
Brandon S. M.,
Bright B.,
Butt M. T.,
Chen D. S.,
Chen P. J.,
Chien R. N.,
Chuang W. L.,
Cuellar D.,
Elbardiny A. A.,
Estes C.,
Farag E.,
Fung J.,
Gamkrelidze I.,
Garcia V.,
Genov J.,
Ghandour Z.,
Ghuloom M.,
Gomez B.,
Gunter J.,
Habeeb J.,
Hajelssedig O.,
Hamoudi W.,
Himatt S. M.,
Hrstic I.,
Hu C. C.,
Huang C. F.,
Hui Y. T.,
Jahis R.,
Jelev D.,
John A. K.,
Kaliaskarova K. S.,
Kamel Y.,
Kao J. H.,
Khamis J.,
Khattabi H.,
Khoudri I.,
Konysbekova A.,
Kotzev I.,
Lai M. S.,
Lao W. C.,
Layden J.,
Lee M. H.,
Lesi O.,
Li M.,
Lo A.,
Loo C. K.,
Lukšić B.,
Maaroufi A.,
Malu A. O.,
Mateva L.,
Mitova R.,
Mohamed R.,
Morović M.,
Murphy K.,
Mustapha B.,
Nersesov A.,
Ngige E.,
Njouom R.,
Njoya O.,
ković D.,
Obekpa S.,
Oguche S.,
Okolo E. E.,
Omuemu C.,
Ondoa P.,
OpareSem O.,
OwusuOfori S.,
Prokopenko Y. N.,
Razavi H.,
RazaviShearer D.,
RazaviShearer K.,
Redae B.,
Reic T.,
Rinke de Wit T.,
Rios C.,
Robbins S.,
Roberts L. R.,
Sanad S. J.,
Schmelzer J. D.,
Sharma M.,
Su T. H.,
Sultan K.,
Tchernev K.,
Tsang O. T. Y.,
Tsang S.,
Tzeuton C.,
Ugoeze S.,
Uzochukwu B.,
Vi R.,
Vince A.,
Wani H. U.,
Wong V. W. S.,
Workneh A.,
Yacoub R.,
Yesmembetov K. I.,
Youbi M.,
Yuen M. F.,
Nde H.
Publication year - 2017
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12760
Subject(s) - medicine , disease burden , population , mortality rate , environmental health , disease
Summary Factors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV‐related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high‐treatment rate will contribute to a reduction in total cases and HCV‐related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV‐related morbidity and mortality.